The compounds are inhibitors of phosphatidylinositol 3-kinase (Pl3K) and are useful for the treatment of conditions mediated by one or more PI3K isoforms.This application also provides Pharmaceutical compositions comprising a compound of formula (1) or taut u00f3meros salts, isomers, pharmaceutically acceptable or mixtures thereof, and Methods for using such compounds and compositions for the treatment of MED One or more iadas PI3K isoforms.Claim 1: a compound characterized by the structure of formula (1) wherein: N is 1, 2 or 3； M is 0 OR 1； each is selected regardless of r u00b9 Halo alkyl, cyano, one to six carbon Atoms optionally replaced, haloalquilo one to six carbon Atoms Or alkoxy optionally substituted, one to six carbon Atoms optionally replaced,Optionally substituted aryl sulfonyl, three to eight carbon Atoms optionally substituted heteroaryl, three to eight carbon Atoms optionally substituted cycloalkyl, three to eight carbon Atoms optionally replaced,And heterocicloalquilo three to eight carbon Atoms optionally substituted； each is independently R u00b2 Halo alkyl and one to six carbon Atoms optionally substituted； r u00b3 is Hydrogen, alkyl one to six carbon Atoms optionally substituted aryl, Six to ten u00e1t Omos carbon optionally replaced,Cycloalkyl or three to eight carbon Atoms optionally substituted heteroaryl； r u2074 is a Six to twelve member has at least one Aromatic Group and at least two heteroatoms selected from N, o or s, which is optionally substituted heteroaryl with one, two or three members I selected regardless of Halo, cyano,Haloalquilo one to six carbon Atoms optionally substituted alkyl, one to six carbon Atoms optionally replaced, Alquinilo two to four carbon Atoms optionally replaced, and nh u2082 r u2075 is Hydrogen or alkyl； and one to six carbon Atoms substituted Choice Finally；Where r u2075 and r u00b3 along with Atoms which are linked to form a Heterocyclic Ring of four to eight members, or a Salt, isomer or a mixture there
